Concepedia

Author

Sung‐Soo Yoon

Seoul National University Hospital

Also Known As

S S Yoon, S.J. Jin Yoon, S.J. Yoon, Siddhartha Jaiswal, Sung-Soo Yoon, Sung-soo Yoon, Sungsoo Yoon, Sung‐Soo Yoon, Yoon, Sung-Soo

104

Publications

612

Citations

14

H-Index

34

Concepts

All Affiliations

Seoul National University HospitalSeoul National UniversityNational and Kapodistrian University of AthensCatholic University of KoreaSamsung Medical Center
SY

About

Sung‐Soo Yoon is an author at Seoul National University Hospital specializing in oncology, medicine, and hematology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

4

4

76

2

Health Sciences

1

1

22

3

Public Health

1

1

14

4

Blood Transplantation

1

1

14

5

Health Policy

1

1

14

Sung‐Soo Yoon

×

19

Publications

422

Citations

14

H-Index

YearCitations

RG6234, a GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Intravenous (IV) and First Subcutaneous (SC) Results from a Phase I Dose-Escalation Study

Carmelo Carlo‐Stella, Rita Mazza, Salomon Manier,

Blood

2022

86

Vantage 095: Vorinostat in Combination with Bortezomib in Salvage Multiple Myeloma Patients: Final Study Results of a Global Phase 2b Trial

David S. Siegel, Meletios Α. Dimopoulos, Sung‐Soo Yoon,

Blood

2011

45

Glutathione <i>S</i>‐transferase A1 polymorphisms and acute graft‐vs.‐host disease in HLA‐matched sibling allogeneic hematopoietic stem cell transplantation

Inho Kim, Bhumsuk Keam, Kyung‐Hun Lee,

Clinical Transplantation

2007

25

Recombinant human epidermal growth factor on oral mucositis induced by intensive chemotherapy with stem cell transplantation

Kyung Im Kim, Ji‐Won Kim, Hyun Jung Lee,

American Journal of Hematology

2012

23

Update on a Phase III Study of Panobinostat with Bortezomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: PANORAMA 1,

Jesús F. San Miguel, Vânia Hungria, Sung‐Soo Yoon,

Blood

2011

22

MOMENTUM: Phase 3 randomized study of momelotinib (MMB) versus danazol (DAN) in symptomatic and anemic myelofibrosis (MF) patients previously treated with a JAK inhibitor.

Ruben A. Mesa, Aaron T. Gerds, Alessandro M. Vannucchi,

Journal of Clinical Oncology

2022

22

Managing cytokine release syndrome (CRS) and neurotoxicity with step-fractionated dosing of mosunetuzumab in relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL).

Nancy L. Bartlett, Laurie H. Sehn, Sarit Assouline,

Journal of Clinical Oncology

2019

21

Subcutaneous Mosunetuzumab Is Active with a Manageable Safety Profile in Patients (pts) with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphomas (B-NHLs): Updated Results from a Phase I/II Study

Lihua E. Budde, Nancy L. Bartlett, Pratyush Giri,

Blood

2022

21

SLC29A1 (ENT1) polymorphisms and outcome of complete remission in acute myeloid leukemia

Jeong‐Hyun Kim, Chansu Lee, Hyun Sub Cheong,

Cancer Chemotherapy and Pharmacology

2016

19

Daratumumab Plus Bortezomib, Melphalan, and Prednisone (D-VMP) Versus Bortezomib, Melphalan, and Prednisone (VMP) Alone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of the Phase 3 Alcyone Study

María‐Victoria Mateos, Jesús F. San Miguel, Michèle Cavo,

Blood

2022

18

Page 1